HealthQuad Fund III First Close Rs 550 Crore: Quadria-Backed VC Targets India’s $600 Billion Healthcare Market
India’s healthcare system needs 500 billion dollars of new investment just to close its current access gap. HealthQuad’s third fund just secured its first close, and its opening bet is already placed on an AI remote monitoring platform called LifeSigns.
India needs to more than double its hospital beds. It needs seven times more clinical professionals than it currently has. And it needs $500 billion in investment to close the gap between the healthcare its population requires and what currently exists. These are not distant projections. They describe the present. Into that gap, HealthQuad has been deploying venture capital since 2016, and its third fund just completed its first close.
HealthQuad Fund III has secured ₹550 crore in initial commitments, representing more than a third of its ₹1,700 crore target. A greenshoe option could expand the total to ₹2,500 crore. The fund is backed by Quadria Group and managed by a leadership team that includes Amit Varma, Abrar Mir and Sunil Thakur, who have led the firm’s prior two funds, alongside newly added partners Rahul Agarwal and Namit Chugh. Investors in this close include both returning LPs from Funds I and II and new limited partners spanning global and domestic funds of funds, institutions and family offices.
The fund has already made its opening investment in LifeSigns, described as India’s leading AI-powered remote patient monitoring platform. That first bet is a deliberate signal about where Fund III is focused: technology that extends care beyond hospital walls and into the daily lives of patients who would otherwise remain unmonitored. Fund III will target 13 to 15 companies across healthtech, medtech, biopharma technology and novel healthcare delivery. The segments the fund is prioritising are growing at 16 to 40 percent annually and are projected to account for over 40 percent of India’s $600 billion healthcare market by 2030.
HealthQuad’s prior portfolio, which includes Qure.ai in radiology AI, Wysa in mental health, Redcliffe Labs in diagnostics and CureSkin in dermatology, demonstrates a consistent bias toward businesses that use technology to reach patients that the formal healthcare system currently misses. Fund III appears to be extending that thesis rather than departing from it, with the LifeSigns bet pointing squarely at the chronic disease monitoring gap in India’s primary care infrastructure. The first close is a credible start. How the fund deploys the remaining capital across 12 to 14 more bets over the next three years will define its legacy.
